Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 0.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,245 shares of the company’s stock after selling 148 shares during the period. Rhumbline Advisers’ holdings in Axsome Therapeutics were worth $4,336,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Creative Planning grew its holdings in Axsome Therapeutics by 29.8% during the 3rd quarter. Creative Planning now owns 10,854 shares of the company’s stock valued at $975,000 after purchasing an additional 2,489 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Axsome Therapeutics by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company’s stock valued at $1,780,000 after purchasing an additional 754 shares during the last quarter. US Bancorp DE lifted its position in Axsome Therapeutics by 0.3% in the 3rd quarter. US Bancorp DE now owns 133,126 shares of the company’s stock valued at $11,964,000 after purchasing an additional 421 shares during the last quarter. Finally, Privium Fund Management B.V. raised its position in shares of Axsome Therapeutics by 7.9% during the 3rd quarter. Privium Fund Management B.V. now owns 80,232 shares of the company’s stock worth $7,210,000 after buying an additional 5,900 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Trading Up 0.9 %

Shares of Axsome Therapeutics stock opened at $127.54 on Friday. The firm has a market capitalization of $6.22 billion, a PE ratio of -21.29 and a beta of 1.05. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The company’s fifty day moving average price is $104.27 and its two-hundred day moving average price is $96.06. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. On average, analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

AXSM has been the topic of several recent research reports. Morgan Stanley lifted their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday. Bank of America raised their price target on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Wells Fargo & Company lifted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Leerink Partners lifted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, February 10th. Finally, Royal Bank of Canada boosted their price objective on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $165.36.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.